ISONIAZID
Activity : Mycobacterium tuberculosis
Mode of action: Prodrug - active intermediate inhibits mycolic acid synthesis (mycolase synthetase)
Metabolism: Acetylation; slow vs rapid: genetically determined; slow acetylation is associated with toxicity
Dose and Administration: oral (IV available); 300mg/day
Absorption: well absorbed
Toxicity: peripheral neuritis and hepatotoxicity